Arcutis Biotherapeutics

ARQT

Market cap $3.03B

WESTLAKE VILLAGE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston.

Arcutis Biotherapeutics delivered a strong Q4 2025, with $127.5M in revenue (+84% YoY) and a GAAP EPS beat, driven by Zoryve's rapid adoption. ARQT is transitioning from a launch-stage biotech to a profitable, high-growth commercial company, with Zoryve now the leading branded nonsteroidal topical in its indications. Valuation is premium at ~9x forward EV/sales but justified by operating leverage, a robust pipeline, and upcoming pediatric/label expansion catalysts.

Arcutis Biotherapeutics, Inc. (ARQT) Q4 2025 Earnings Call Transcript

Arcutis Biotherapeutics, Inc. (ARQT) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.09 per share a year ago.

Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025 Full year 2025 net product revenue for ZORYVE was $372.1 million, an increase of 123% over the prior year Reported positive topline data for the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% in children ages 3 to 24 months with mild to moderate atopic dermatitis, with a Supplemental New Drug Application (sNDA) submission expected in Q2 2026 Announced expansion of its dermatology sales force and, separately, the initiation of a targeted Arcutis commercialization effort for primary care and pediatric health care providers Produced positive operating cash flow in Q4 2025 and anticipates maintaining positive operating cash flow on a quarterly basis going forward Company raised 2026 full year net product sales guidance to $480 million – $495 million WESTLAKE VILLAGE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter and year ended December 31, 2025, and provided a business update.

Max Homa shares his journey with seborrheic dermatitis to encourage others to take control of their symptoms ZORYVE® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniquely formulated to treat the itching, redness, and flaking of seborrheic dermatitis anywhere it appears, including hair-bearing areas 10 million Americans live with seborrheic dermatitis, a chronic inflammatory skin disease that occurs most often on areas with oil-producing glands, including the face and scalp WESTLAKE VILLAGE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that six-time PGA Tour winner Max Homa has joined the company's Free to Be Me awareness campaign to help encourage the millions of Americans living with seborrheic dermatitis (seb derm) to speak with their healthcare providers about long-term treatment options.

Arcutis Biotherapeutics shifts to Hold after a 100% rally, as much of the initial de-risked growth thesis has played out. ZORYVE approvals and revenue growth have driven a fair rerating, but forward expectations now imply slower compounding and less favorable risk/reward. ARQT's long-term upside remains via steroid market conversion and pipeline optionality, yet near-term catalysts are limited and growth deceleration is expected.

Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tejara Capital sold 520,503 shares of Arcutis Biotherapeutics in the fourth quarter. The quarter-end position value decreased by $9.81 million, reflecting the full exit and price changes.

WESTLAKE VILLAGE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 94,000 restricted stock units of Arcutis' common stock to 12 newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of February 2, 2026, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).